T. cruzi-seropositivity associated with higher incidence of cardiomyopathy: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-10-11 04:00 GMT   |   Update On 2021-10-11 07:49 GMT
Advertisement

According to a study published in the Circulation, T. cruzi-seropositivity is associated with a higher incidence of cardiomyopathy.

There are few contemporary cohorts of Trypanosoma cruzi-seropositive individuals, and the basic clinical epidemiology of Chagas disease is poorly understood. A team of researchers conducted a study to report the incidence of cardiomyopathy and death associated with T. cruzi seropositivity.

Advertisement

Participants were selected in blood banks at 2 Brazilian centres. Cases were defined as T. cruzi-seropositive blood donors. T. cruzi-seronegative controls were matched for age, sex, and period of donation. Patients with established Chagas cardiomyopathy were recruited from a tertiary outpatient service. Participants underwent a medical examination, blood collection, electrocardiogram, and echocardiogram at enrollment (2008 to 2010) and at follow-up (2018 to 2019). The primary outcomes were all-cause mortality and development of cardiomyopathy, defined as the presence of a left ventricular ejection fraction <50% and/or QRS complex duration ≥ 120 ms. To handle a loss to follow-up, a sensitivity analysis was performed using inverse probability weights for selection.

The results of the study are as follows:

· They enrolled 499 T. cruzi-seropositive donors, 488 T. cruzi-seronegative donors, and 101 patients with established Chagas cardiomyopathy.

· The mortality in patients with established cardiomyopathy was 80.9 deaths/1000 person-years (py) and 15.1 deaths/1000 py in T. cruzi-seropositive with cardiomyopathy at baseline.

· Among T. cruzi-seropositive donors without cardiomyopathy at baseline mortality was 3.7 events/1000py (15/385, 4%), which was no different from T. cruzi-seronegative donors with 3.6 deaths/1000py (17/488, 3%).

· The incidence of cardiomyopathy in T. cruzi-seropositive donors was 13.8 compared with 4.6 events/1000 py (11/277, 4%) in seronegative controls, with an absolute incidence difference associated with T. cruzi seropositivity of 9.2 events/1000py. T. cruzi antibody level at baseline was associated with the development of cardiomyopathy.

Thus, the researchers concluded by presenting a comprehensive description of the natural history of T. cruzi seropositivity in a contemporary patient population. The results highlight the central importance of anti-T. cruzi antibody titer as a marker of Chagas disease activity and risk of progression.

Reference:

Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up of Trypanosoma Cruzi Seropositive Individuals by Nunes M et. al published in the Circulation.

https://doi.org/10.1161/CIRCULATIONAHA.121.055112


Tags:    
Article Source : Circulation

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News